1 / 14

Chemotherapy of bacterial infections. Part II.

Chemotherapy of bacterial infections. Part II. Antibiotics – after-effects :. Origin of drug resistance: intrinsic - inherent , natural acquired

molly
Download Presentation

Chemotherapy of bacterial infections. Part II.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chemotherapy of bacterial infections. Part II.

  2. Antibiotics –after-effects:

  3. Origin of drug resistance: intrinsic - inherent, natural acquired • nongenetic - lack of active replication- loss of the specific target structure (L-forms) - infection ocurring at sites where antimicrobials are excluded or not active

  4. genetic- chromosomal resistance: mutation  resistant mutants selectiono stable • o allow vertical transmission of resistance only (descending) • o allow no horizontal transmission: not transferable from one bacterium to another • o these genes cause intrinsic resistance

  5. Macrolide-Lincosamide-Streptogramin Resistance • The MLS group: macrolides, lincosamides and streptogramins (A and B); resistance - due to efflux, target modification, drug enzymatic modification. • In staphs, erythromycin resistance is caused by the erm gene codingan enzyme which modifies the ribosome NONE of these antibiotics may bind to the ribosome.If the erm gene product is constitutively produced, testing will find the staph resistant to all of the MLS antibiotics.If the erm gene product is inducibly produced, it will only be expressed when the organism is exposed to a macrolide C14 and C15, but not C16 and ketolides.

  6. Acquired Resistance to Aminoglycosides • mainly enzymatic drug modification • KanHCGenHC - HLAR E. faecalis • IntermediateIntermediateSynergy with B-lactam and Kan or Gen • ResistantResistantNo synergy with B-lactam and Kan or Gen • ResistantIntermediateNo synergy with B-lactam and Kan

  7. Glycopeptide resistance • GISA, VISAglycopeptide, vancomycin intermediate susceptible Staphylococcus aureus • Enterococci have natural susceptibility to vancomycin, except E. casseliflavus and E. galinarum (natural resistance to vancomycin).vanAvanBvanC • · vanA confers high level resistance to vancomycin • · vanB confers moderate level resistance to vancomycin • · vanC causes intrinsic vancomycin resistance in E. gallinarum and E. casseliflavus • VRE (Vancomycin Resistant Enterococci) refers to E.fecalis or E.faecium, which are normally sensitive to vancomycin. Vancomycin resistance in these organisms is due to the acquisition of vanA or vanB.

More Related